Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases

International Journal of Biological Markers

Volumn 17, Issue 4, 2002, Pages 244-252

  Berruti, A ^a   Dogliotti, Luigi ^a   Tucci, M ^a   Tarabuzzi, R ^a   Guercio, S ^a   Torta, M ^a   Tampellini, M ^a   Dovio, A ^a   Poggio, M ^a   Scarpa, R M ^a   Angeli, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bisphosphonates; Bone metastases; Bone pain; Bone turnover markers; Prostatic neoplasms

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN TYPE 1 C TELOPEPTIDE; DEOXYPYRIDINOLINE; GONADORELIN DERIVATIVE; HORMONE; HYDROXYPROLINE; INTERLEUKIN 6; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PYRIDINOLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BONE DEVELOPMENT; BONE METASTASIS; BONE PAIN; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INFUSION; DRUG MONITORING; HORMONAL THERAPY; HUMAN; INHIBITION KINETICS; MALE; METABOLIC PARAMETERS; OSTEOLYSIS; PREDICTION; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SYMPTOM;

EID: 0036822229     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.2194     Document Type: Article

References (38)

1. Galasko CBS. The anatomy and pathway of skeletal metastases. In: Weiss L, Gilbert AH, eds. Bone Metastases. Boston: Hall GH, 1981; 49-63.
2. Rubens RD, Fogelman I. Bone Metastases: Diagnosis and Treatment. London: Springer-Verlag, 1991; 50-3.
3. Guise AT, Mundy GR. Cancer and bone. Endocrine Rev 1998; 19: 18-54.
4. Francini G, Montagnani M, Petrioli R, Paffetti P, Marsili S, Leone V. Comparison between CEA, TPA, CA 15-3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Int J Biol Markers 1990; 5: 65-72.
5. Urwin GH, Percival RC, Harris S, Beneton MN, William JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721-3.
6. Taube T, Beneton MNC, Williams JL, McCloskey EV, Kanis JA. Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastatised to bone. Br J Urol 1993; 72: 98-103.
7. Lipton A, Demers L, Daniloff Y, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 1993; 39: 614-8.
8. Piovesan A, Berruti A, Osella G, et al. Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastases. Int J Biol Markers 1994; 9: 243-6.
9. Berruti A, Piovesan A, Torta M, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension. Br J Cancer 1996; 73: 1581-7.
10. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer 1997; 80 (Suppl 8): 1538-45.
11. Berruti A, Sperone P, Fasolis G, et al. Pamidronate administration improves the secondary hyperparathyroidism due to "bone hunger syndrome" in a patient with osteoblastic metastases from prostate cancer. Prostate 1997; 33: 252-5.
12. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58 (Suppl 1): 101-6.
13. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-7.
14. Lepor H, Ross A, Walsh PC. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982; 128: 335-40.
15. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in prostate cancer patients with hormone refractory disease. Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-53.
16. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80 (Suppl 8): 1588-94.
17. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999; 45: 1240-7.
18. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998; 16: 3890-9.
19. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. Metabolic bone disease induced by prostate cancer. Rationale for the use of bisphosphonates. J Urol 2001; 166: 2023-31.
20. Delmas PD. Biochemical markers of bone turnover. J Bone Min Res 1993; 8 (Suppl 2): 549-55.
21. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman R. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996; 73: 1089-95.
22. Vinholes JF, Purohit OP, Abbey NE, Eastell R, Coleman R. Relationships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic disease. Ann Oncol 1997; 8: 1243-50.
23. Coleman RE. Evaluation of bone disease in breast cancer. Breast 1993; 3: 73-8.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
25. Statsoft Inc. Statistica for Windows. Rel. 5.0. 2325 East 13th Street Tulsa OK 1995; 74104.
26. Blumshon A, Naylor KE, Assiri AMA, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem 1995; 41: 1592-8.
27. Pecherstorfer M, Schilling T, Janisch S, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993; 34: 1039-44.
28. Coleman RE, Vinholes J, Purohit A, Milford-Ward A. Effects of pamidronate on tumor marker levels in breast and prostate cancer. Correlation with clinical and biochemical response. Proceedings of the Thirty-third Annual Meeting of the American Society of Clinical Oncology. Denver: American Society of Clinical Oncology, 1997; 16: 1179 (abstract).
29. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997; 80: 1674-9.
30. Schwetzer DH, Oostendorp-Van De Reuit M, Van Der Pluijm G, Lowik CWGM, Papalopoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956-62.
31. Lissoni P, Cazzaniga M, Barni S, et al. Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumor patients with bone metastases and their possible complications in the immunotherapy of cancer with interleukin-2. Eur J Cancer 1997; 33: 304-6.
32. Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997; 61: 386-92.
33. Sauty A, Pecherstofer M, Zimmer-Roth I, et al. Interleukin-6 and tumour necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996; 18: 133-9.
34. Scheidt-Nave C, Bismar H, Leidig-Brunckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001; 86: 2032-42.
35. Mitnick MA, Grey A, Masiukiewicz U, et al. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab 2001; 280: E405-12.
36. Millet I, McCarthy TL, Vignery A. Regulation of interleukin-6 production by prostaglandin E2 in fetal rat osteoblasts: Role of protein kinase A signaling pathway. J Bone Miner Res 1998; 13: 1092-100.
37. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H. Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 121-5.
38. Cocco R, Tofi C, Fioravanti A, et al. Effects of clodronate on synovial fluid levels of some inflammatory mediators, after intra-articular administration to patients with synovitis secondary to knee osteoarthritis. Boll Soc Ital Biol Sper 1999; 75: 71-6.